|
Who Is Doing This Study?
Schering-Plough Research Institute has selected Pacific Fertility Center as one of about 35 study sites located in the United States to participate.
Why Are We Doing This Study?
The purpose of this study is to evaluate the effectiveness and safety of a single injection of corifollitropin alfa (an investigational drug) in inducing the development of multiple follicles, compared to daily injections of recFSH (300 IU [international units]). The number of fetuses (unborn babies) with heart activity (also referred to as a vital pregnancy) conceived in study subjects, along with the number of growing follicles, the number of eggs retrieved, the number of viable (good quality) embryos and the number of babies born will be determined as part of the objectives of this study.
Who is eligible?
Females who are:
-
Suffering from infertility
-
35-42 years of age
-
Weigh at least 110.3 lbs and have a Body Mass Index (BMI) of at least 18 but no more than 32
-
Have regular spontaneous menstrual cycles every 24 to 35 days
-
Will use their partner’s sperm derived from ejaculation or that of a sperm donor
This list is not all-inclusive. If you have questions regarding your eligibility to participate in this study, or would like to schedule an appointment for an evaluation, please contact us at 415-834-3095.
NO LONGER ENROLLING
| 
